Literature DB >> 21153577

[Qualitative differences between ranibizumab from original and ready to use syringes].

S Grisanti1, A Tura.   

Abstract

OBJECTIVE: The aim of this study was to determine the influence of time, temperature and light exposure on ranibizumab (Genentech, San Francisco, USA) in plastic syringes.
METHODS: Samples of ranibizumab were drawn from the original vials into plastic tuberculin syringes, capped and analyzed after different storage intervals under varying temperature conditions (4 °C and room temperature) and light exposure (protected and room light). The samples were tested for the pH value, protein stability and concentration as well as for the binding affinity to VEGF-165 in an ELISA (enzyme linked immunoassay). Additionally, original freshly drawn samples were compared to commercially available ready to use ranibizumab syringes analyzed up to 14 days after sampling.
RESULTS: Samples stored under the described conditions retained a stable pH. Both SDS-PAGE analysis as well as protein concentration measurements shows slightly decreasing values over time that were not additionally influenced by light exposure or room temperature. The binding affinity to VEGF-165, however, was significantly decreased (p<0.05) over time starting from the first day after sampling. A similar effect could be observed in commercially available ready to use syringes. Exposure to light and room temperature led to additional decreases in the binding affinity to VEGF-165.
CONCLUSION: Until now different socioeconomic and legal aspects have influenced the choice whether to use original vials or pre-sampled ranibizumab. A new aspect is the effect of storage in plastic syringes on the quality and biological efficacy of the antibody fragment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153577     DOI: 10.1007/s00347-010-2299-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  8 in total

1.  High-molecular-weight aggregates in repackaged bevacizumab.

Authors:  Malik Y Kahook; Lu Liu; Philip Ruzycki; Naresh Mandava; John F Carpenter; J Mark Petrash; David A Ammar
Journal:  Retina       Date:  2010-06       Impact factor: 4.256

2.  Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Authors:  David S Boyer; Andrew N Antoszyk; Carl C Awh; Robert B Bhisitkul; Howard Shapiro; Nisha R Acharya
Journal:  Ophthalmology       Date:  2007-02       Impact factor: 12.079

3.  Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells.

Authors:  Swaantje Peters; Sylvie Julien; Peter Heiduschka; Salvatore Grisanti; Focke Ziemssen; Martin Adler; Ulrich Schraermeyer; Karl-Ulrich Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

4.  Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing.

Authors:  Sophie J Bakri; Melissa R Snyder; Jose S Pulido; Colin A McCannel; William T Weiss; Ravinder J Singh
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

5.  Accuracy and precision of intravitreally injected ranibizumab doses: an experimental study.

Authors:  H Gerding; M Timmermann
Journal:  Klin Monbl Augenheilkd       Date:  2010-04-20       Impact factor: 0.700

6.  Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months.

Authors:  Yi-Hao Chen; Pei-Chang Wu; Jentaie Shiea; Li-Hua Lo; Yi-Chen Wu; Hsi-Kung Kuo
Journal:  J Ocul Pharmacol Ther       Date:  2009-02       Impact factor: 2.671

7.  [Volume calculations for current intravitreal injections of Lucentis].

Authors:  A Wolf; A Gandorfer; C Haritoglou; C Koller; A Thalmeier; A Kampik
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

8.  Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.

Authors:  Peter K Kaiser; David M Brown; Kang Zhang; Henry L Hudson; Frank G Holz; Howard Shapiro; Susan Schneider; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2007-10-22       Impact factor: 5.258

  8 in total
  4 in total

1.  Influence of seasonal sunlight intensity and iris color on the anti-VEGF therapy for neovascular age-related macular degeneration.

Authors:  C Brockmann; T Brockmann; J Dawczynski
Journal:  Eye (Lond)       Date:  2013-08-02       Impact factor: 3.775

Review 2.  Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.

Authors:  C H Meyer; F G Holz
Journal:  Eye (Lond)       Date:  2011-04-01       Impact factor: 3.775

3.  Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties.

Authors:  Magne Sand Sivertsen; Øystein Kalsnes Jørstad; Algirdas Grevys; Stian Foss; Morten Carstens Moe; Jan Terje Andersen
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

4.  A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.

Authors:  Heidrun Elisabeth Lode; Torleif Tollefsrud Gjølberg; Stian Foss; Magne Sand Sivertsen; Jørgen Brustugun; Yvonne Andersson; Øystein Kalsnes Jørstad; Morten Carstens Moe; Jan Terje Andersen
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.